Next-generation CRISPR screens to fast-forward drug discovery

Our technology platform

At Myllia, we perform pooled CRISPR screens in advanced cellular models such as primary human immune cells to map the impact of thousands of genetic perturbations at single-cell resolution – a new paradigm to nominate the best possible targets for your drug discovery campaign.

Our scalable functional genomics platform enables tailor-made CRISPR screens in single cells and involves bespoke assay development according to your specific needs:

Technology
Circles representing the technology platform for genetic perturbation CRISPR drug screens built at Myllia Biotechnology.

CRISPR screening applications for drug discovery

Pooled CRISPR screens accelerate drug discovery across many therapeutic areas and help unravel gene regulatory networks in cancer cells and primary human immune cells, e.g., primary T cells and myeloid cells. We utilize CRISPR knockout, CRISPR interference and CRISPR activation for genetic perturbation combined with high-throughput functional genomics read-outs.

Myllia’s CROP-Seq perturbation datasets can also be utilized at unprecedented scale to enable the training of artificial intelligence (AI) models. For instance, such AI/ML-based foundation models will help create digital avatars of human cells to predict phenotypic changes caused by CRISPR perturbation and “matched” drug perturbation data.

Learn more about our CRISPR screening platform for high-content data generation across many applications:

Applications
Target icon symbolising crispr screen target identification and validation

Drug target ID/validation incl. target deconvolution and identification of disease-associated gene function using functional genomics

Screen in blue with an ascending graph representing the CRISPR screen analysis.

Mode of action (MoA) analysis and drug signature CRISPR screening

DNA icon in blue to illustrate the identification of disease-associated gene functions.

CROP-Seq perturbation datasets for training of AI/ML-based foundation models of human cell biology

Network icon in blue to illustrate the genetic perturbation screening of primary T cell subsets.

Pooled CRISPR screens in human-centric, primary immune models, e.g., primary helper T cells and myeloid cells

Genetic perturbation screens and functional genomics at single-cell resolution revolutionize the way we identify novel drug targets and gene regulatory networks involved in oncology and autoimmune disease.